These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24969795)

  • 1. The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy.
    Yu JI; Park HC; Lim DH; Choi Y; Jung SH; Paik SW; Kim SH; Jeong WK; Kim YK
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):814-21. PubMed ID: 24969795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
    Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
    Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?
    Vouche M; Salem R; Lewandowski RJ; Miller FH
    Abdom Imaging; 2015 Aug; 40(6):1471-80. PubMed ID: 25412868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; Qiu D; Kitajima H; Mittal PK; Kim HS
    Abdom Imaging; 2014 Oct; 39(5):969-78. PubMed ID: 24740759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data.
    Bonekamp S; Jolepalem P; Lazo M; Gulsun MA; Kiraly AP; Kamel IR
    Radiology; 2011 Sep; 260(3):752-61. PubMed ID: 21771960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
    Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
    J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Added value of diffusion-weighted MRI for evaluating viable tumor of hepatocellular carcinomas treated with radiotherapy in patients with chronic liver disease.
    Park HJ; Kim SH; Jang KM; Lim S; Kang TW; Park HC; Choi D
    AJR Am J Roentgenol; 2014 Jan; 202(1):92-101. PubMed ID: 24370133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
    Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
    J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations.
    Eccles CL; Haider EA; Haider MA; Fung S; Lockwood G; Dawson LA
    Acta Oncol; 2009; 48(7):1034-43. PubMed ID: 19634060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging.
    Rhee TK; Naik NK; Deng J; Atassi B; Mulcahy MF; Kulik LM; Ryu RK; Miller FH; Larson AC; Salem R; Omary RA
    J Vasc Interv Radiol; 2008 Aug; 19(8):1180-6. PubMed ID: 18656011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma.
    Oldrini G; Huertas A; Renard-Oldrini S; Taste-George H; Vogin G; Laurent V; Salleron J; Henrot P
    PLoS One; 2017; 12(4):e0176118. PubMed ID: 28441447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can preoperative diffusion-weighted MRI predict postoperative hepatic insufficiency after curative resection of HBV-related hepatocellular carcinoma? A pilot study.
    Kim SU; Kim YC; Choi JS; Kim KS; Choi GH; Choi JS; Park JY; Kim DY; Ahn SH; Choi EH; Park YN; Chon CY; Han KH; Kim MJ
    Magn Reson Imaging; 2010 Jul; 28(6):802-11. PubMed ID: 20395100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience.
    Mannelli L; Kim S; Hajdu CH; Babb JS; Taouli B
    Eur J Radiol; 2013 Apr; 82(4):577-82. PubMed ID: 23246330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging.
    Catalano OA; Choy G; Zhu A; Hahn PF; Sahani DV
    Radiology; 2010 Jan; 254(1):154-62. PubMed ID: 20032150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy.
    Kim KA; Park MS; Ji HJ; Park JY; Han KH; Kim MJ; Kim KW
    J Magn Reson Imaging; 2014 Feb; 39(2):286-92. PubMed ID: 24302545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-month apparent diffusion coefficient correlates with response to radiofrequency ablation of hepatocellular carcinoma.
    Barat M; Fohlen A; Cassinotto C; Jannot AS; Dautry R; Pelage JP; Boudiaf M; Pocard M; Eveno C; Taouli B; Soyer P; Dohan A
    J Magn Reson Imaging; 2017 Jun; 45(6):1648-1658. PubMed ID: 27766709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
    Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging after radiation therapy for bone metastases in patients with hepatocellular carcinoma.
    Lee JH; Yoo GS; Yoon YC; Park HC; Kim HS
    Sci Rep; 2021 May; 11(1):10459. PubMed ID: 34001997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma: correlation with enhancement degree and histologic grade.
    Woo S; Lee JM; Yoon JH; Joo I; Han JK; Choi BI
    Radiology; 2014 Mar; 270(3):758-67. PubMed ID: 24475811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.